Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
Earnings Data
Report Date
Feb 05, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.58Last Year’s EPS
-4.08Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
While the company has achieved significant progress with the successful Phase 3 trial and sees a large opportunity in the U.S. market, it faces challenges in Europe with declining revenues and specific market issues in Germany and Spain. Financial metrics also indicate an increased operating loss, although the cash position and gross margin have improved.Company Guidance
Successful Phase 3 ConfIdeS Trial Outcome
The Phase 3 ConfIdeS trial showed a strong p-value of 0.0001, indicating significant unmet medical need for highly sensitized patients. This supports the forthcoming BLA filing in the U.S.
U.S. Market Opportunity
The U.S. market represents a significant growth opportunity with 15,000 highly sensitized patients on the transplant waitlist and robust clinical data supporting a potential launch in the second half of 2026, subject to FDA approval.
Strong Cash Position
The company reported cash and cash equivalents of SEK 252.1 million, increasing to SEK 888 million including net proceeds from a recent capital raise.
Improved Gross Margin
The company's gross margin for the nine months ended September 30, 2025, was 60%, up from 50% for the same period in 2024.
SE:HNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:HNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | kr34.46 | kr30.66 | -11.03% |
Jul 17, 2025 | kr25.94 | kr27.90 | +7.56% |
Apr 24, 2025 | kr22.30 | kr23.68 | +6.19% |
Feb 06, 2025 | kr33.62 | kr27.10 | -19.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hansa Biopharma AB (SE:HNSA) report earnings?
Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).
What is Hansa Biopharma AB (SE:HNSA) earnings time?
Hansa Biopharma AB (SE:HNSA) earnings time is at Feb 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hansa Biopharma AB stock?
The P/E ratio of Hansa Biopharma AB is N/A.
What is SE:HNSA EPS forecast?
SE:HNSA EPS forecast for the fiscal quarter 2025 (Q4) is -1.58.